Drug Trial Radar · NCT00266136
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,500
Actual
Start
Jun 1999
Primary completion
Jan 2007
Study completion Oct 2012
Sponsor
- Lead sponsor
- University Hospital MuensterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Deutsche Krebshilfe e.V., Bonn (Germany); German Federal Ministry of Education and Research
- First posted
- Dec 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study in patients with primary and secondary AML and high-risk MDS uses a risk-stratified, randomized design to evaluate the role of high-dose araC in induction, of G-CSF priming, and of autologous stem cell transplantation.
Conditions
- Acute Myeloid Leukemia
Interventions
CytarabineDrug
see protocol
ThioguanineDrug
see protocol
DaunorubicinDrug
see protocol
CyclophosphamideDrug
see protocol
G-CSFDrug
see protocol
Autologous stem cell transplantationProcedure
for details see protocol
Allogeneic stem cell transplantationProcedure
for details see protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Remission rate, Remission duration,Relapse-free survival, Overall survival, Event-free survivalTime frame: 12-18months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology
Münster, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.